Summary

Triton’s research report states that the Middle East and Africa surgical site infection control market is estimated to register a CAGR of 4.56% during the forecast period 2024-2032.
The surgical site infection (SSI) control market’s development in the Middle East and Africa (MEA) is accelerated by rising healthcare awareness, government initiatives, and international collaborations aimed at improving healthcare infrastructure. The World Health Organization (WHO) and various regional health ministries have been actively involved in initiatives to reduce SSIs, which are a significant cause of morbidity and mortality. In countries like Saudi Arabia and South Africa, there has been a significant push towards improving hospital hygiene and infection control measures supported by government funding and international partnerships.
The countries analyzed in this region are UAE, South Africa, Israel, Turkey, and Rest of Middle East & Africa.
Saudi Arabia leads the regional market, obtaining $66.9 million in 2023
● The growth of the surgical site infection control market in Saudi Arabia is strongly driven by the government’s Vision 2030 initiative, which aims to modernize the healthcare sector and improve patient safety.

● The Saudi Ministry of Health has implemented stringent guidelines and infection control protocols in hospitals to reduce the incidence of surgical site infections (SSIs). The introduction of advanced sterilization techniques, antimicrobial dressings, and preventive measures are increasingly being adopted across healthcare facilities.


● The Saudi Centers for Disease Control and Prevention (Saudi CDC) provides specific guidelines for SSI prevention, including the use of prophylactic antibiotics, proper hand hygiene, and enhanced sterilization protocols. These guidelines have been widely adopted, leading to increased demand for infection control products and technologies.
Market Forecast for Turkey
In Turkey, the surgical site infection (SSI) control market is fueled by healthcare awareness and government initiatives aimed at improving patient safety. In 2022, surgical site infections remained a critical concern for Turkey’s healthcare system, particularly in procedures like cesarean sections and other high-frequency surgeries. The Ministry of Health in Turkey has been actively working on reducing healthcare-associated infections through various programs, including mandatory infection control measures in hospitals and the implementation of international best practices. The market is further supported by the increasing number of hospitals and the growing use of minimally invasive surgeries, which require stringent infection prevention measures.
The market segmentation includes industry vertical, procedure, type of infection, and product. The industry vertical section consists of hospitals and ambulatory surgical centers.
Surgical site infections (SSIs) account for approximately 15% of all hospital-acquired infections, making them the most common infection among surgical patients. These infections significantly extend postoperative hospital stays, increase healthcare costs, elevate the likelihood of readmission, and compromise patient outcomes. SSIs, which occur at or near surgical incisions within 30 days after surgery, contribute heavily to surgical complications and mortality annually.
Contender Analysis in the Surgical Site Infection Control Market:
3M is a diversified technology firm with operations across multiple industries, including industrial, safety and graphics, electronics and energy, healthcare, and consumer markets. Headquartered in Saint Paul, Minnesota, 3M has a global presence in the United States, Europe, the Middle East and Africa (EMEA), and the Asia Pacific. The company operates through five main business segments: industrial, safety and graphics, health care, electronics and energy, and consumer. The company also specializes in precision grinding technology for intricate industrial applications, and it develops advanced technical ceramics for use in sectors like automotive, oil and gas, solar, electronics, and defense.

Other companies in the market consist of American Polyfilm Inc, Ansell Limited, Belimed Life Science AG, and Gama Healthcare.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1. MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. IMPACT ANALYSIS ON THE SURGICAL SITE INFECTION CONTROL MARKET
2.1.1. COVID-19 IMPACT
2.2. PORTER’S FIVE FORCES ANALYSIS
2.2.1. THREAT OF NEW ENTRANTS
2.2.2. THREAT OF SUBSTITUTES
2.2.3. BARGAINING POWER OF BUYERS
2.2.4. BARGAINING POWER OF SUPPLIERS
2.2.5. THREAT OF COMPETITIVE RIVALRY
2.3. KEY MARKET STRATEGIES
2.3.1. PRODUCT LAUNCHES
2.3.2. ACQUISITIONS
2.3.3. BUSINESS DIVESTITURES & EXPANSIONS
2.4. MARKET DRIVERS
2.4.1. ESCALATING INCIDENCE OF HOSPITAL-ACQUIRED INFECTIONS
2.4.2. GROWING GERIATRIC POPULATION
2.4.3. REGULATORY GUIDELINES FOR PREVENTING HOSPITAL-ACQUIRED INFECTION
2.5. MARKET CHALLENGES
2.5.1. INCREASE IN OUTPATIENT TREATMENT
2.5.2. SURGE IN MEDICAL WASTE DUE TO THE USE OF DISPOSABLE MEDICAL ITEMS
2.5.3. INSUFFICIENT AWARENESS REGARDING HOSPITAL-ACQUIRED INFECTIONS
2.6. MARKET OPPORTUNITIES
2.6.1. GROWTH OF MINIMALLY INVASIVE AND OUTPATIENT SURGICAL PRACTICES
2.6.2. RISE IN SURGICAL PROCEDURE RATES
2.6.3. TECHNOLOGICAL ADVANCEMENTS IN PREVENTING SURGICAL SITE INFECTIONS
2.7. ANALYST PERSPECTIVE
3. MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET – BY PROCEDURE
3.1. LAPAROSCOPY
3.2. ORTHOPEDIC SURGERY
3.3. CARDIOVASCULAR
3.4. OBSTETRICS AND GYNECOLOGY
3.5. WOUND CLOSURE
3.6. PLASTIC & RECONSTRUCTIVE SURGERY
3.7. THORACIC SURGERY
3.8. MICROVASCULAR
3.9. UROLOGY
3.10. NEUROSURGERY
3.11. OTHER PROCEDURES
4. MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET – BY TYPE OF INFECTION
4.1. SUPERFICIAL INCISIONAL SSI
4.2. DEEP INCISIONAL SSI
4.3. ORGAN OR SPACE SSI
5. MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET – BY INDUSTRY VERTICAL
5.1. HOSPITALS
5.2. AMBULATORY SURGICAL CENTERS
6. MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET – BY PRODUCT
6.1. DISINFECTANTS
6.1.1. SKIN DISINFECTANTS
6.1.2. HAND DISINFECTANTS
6.2. MANUAL REPROCESSORS SOLUTIONS
6.3. SURGICAL DRAPES
6.4. SURGICAL GLOVES
6.5. SKIN PREPARATION SOLUTIONS
6.6. SURGICAL IRRIGATION
6.7. SURGICAL SCRUBS
6.8. HAIR CLIPPERS
6.9. MEDICAL NONWOVENS
6.10. OTHER PRODUCTS
7. MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET – BY COUNTRY OUTLOOK
7.1. MIDDLE EAST AND AFRICA
7.1.1. COUNTRY ANALYSIS
7.1.1.1. UNITED ARAB EMIRATES
7.1.1.1.1. UNITED ARAB EMIRATES SURGICAL SITE INFECTION CONTROL MARKET FORECAST & PROSPECTS
7.1.1.2. SAUDI ARABIA
7.1.1.2.1. SAUDI ARABIA SURGICAL SITE INFECTION CONTROL MARKET FORECAST & PROSPECTS
7.1.1.3. TURKEY
7.1.1.3.1. TURKEY SURGICAL SITE INFECTION CONTROL MARKET FORECAST & PROSPECTS
7.1.1.4. SOUTH AFRICA
7.1.1.4.1. SOUTH AFRICA SURGICAL SITE INFECTION CONTROL MARKET FORECAST & PROSPECTS
7.1.1.5. ISRAEL
7.1.1.5.1. ISRAEL SURGICAL SITE INFECTION CONTROL MARKET FORECAST & PROSPECTS
7.1.1.6. REST OF MIDDLE EAST & AFRICA
7.1.1.6.1. REST OF MIDDLE EAST & AFRICA SURGICAL SITE INFECTION CONTROL MARKET FORECAST & PROSPECTS
8. COMPETITIVE LANDSCAPE
8.1. AMERICAN POLYFILM INC
8.1.1. OVERVIEW
8.1.2. PORTFOLIO
8.1.3. KEY STRENGTHS
8.1.4. KEY CHALLENGES
8.2. 3M
8.2.1. OVERVIEW
8.2.2. PORTFOLIO
8.2.3. KEY STRENGTHS
8.2.4. KEY CHALLENGES
8.3. ANSELL LIMITED
8.3.1. OVERVIEW
8.3.2. PORTFOLIO
8.3.3. KEY STRENGTHS
8.3.4. KEY CHALLENGES
8.4. BELIMED LIFE SCIENCE AG
8.4.1. OVERVIEW
8.4.2. PORTFOLIO
8.4.3. KEY STRENGTHS
8.4.4. KEY CHALLENGES
8.5. BECTON, DICKINSON AND COMPANY (BD)
8.5.1. OVERVIEW
8.5.2. PORTFOLIO
8.5.3. KEY STRENGTHS
8.5.4. KEY CHALLENGES
8.6. BIOMERIEUX SA
8.6.1. OVERVIEW
8.6.2. PORTFOLIO
8.6.3. KEY STRENGTHS
8.6.4. KEY CHALLENGES
8.7. GETINGE AB
8.7.1. OVERVIEW
8.7.2. PORTFOLIO
8.7.3. KEY STRENGTHS
8.7.4. KEY CHALLENGES
8.8. GAMA HEALTHCARE
8.8.1. OVERVIEW
8.8.2. PORTFOLIO
8.8.3. KEY STRENGTHS
8.8.4. KEY CHALLENGES
8.9. JOHNSON & JOHNSON
8.9.1. OVERVIEW
8.9.2. PORTFOLIO
8.9.3. KEY STRENGTHS
8.9.4. KEY CHALLENGES
8.10. SOTERA HEALTH LLC
8.10.1. OVERVIEW
8.10.2. PORTFOLIO
8.10.3. KEY STRENGTHS
8.10.4. KEY CHALLENGES
8.11. KIMBERLY-CLARK CORPORATION
8.11.1. OVERVIEW
8.11.2. PORTFOLIO
8.11.3. KEY STRENGTHS
8.11.4. KEY CHALLENGES
8.12. STERIS CORPORATION
8.12.1. OVERVIEW
8.12.2. PORTFOLIO
8.12.3. KEY STRENGTHS
8.12.4. KEY CHALLENGES
8.13. STRYKER CORPORATION
8.13.1. OVERVIEW
8.13.2. PORTFOLIO
8.13.3. KEY STRENGTHS
8.13.4. KEY CHALLENGES
9. RESEARCH METHODOLOGY & SCOPE
9.1. RESEARCH SCOPE & DELIVERABLES
9.2. SOURCES OF DATA
9.3. RESEARCH METHODOLOGY


LIST OF TABLES
TABLE 1: MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY COUNTRY OUTLOOK, 2024-2032 (IN $ MILLION)
TABLE 2: LIST OF PRODUCT LAUNCHES
TABLE 3: LIST OF ACQUISITIONS
TABLE 4: LIST OF BUSINESS DIVESTITURES & EXPANSIONS
TABLE 5: MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY PROCEDURE, 2024-2032 (IN $ MILLION)
TABLE 6: MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY TYPE OF INFECTION, 2024-2032 (IN $ MILLION)
TABLE 7: MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY INDUSTRY VERTICAL, 2024-2032 (IN $ MILLION)
TABLE 8: MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY PRODUCT, 2024-2032 (IN $ MILLION)
TABLE 9: MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY COUNTRY OUTLOOK, 2024-2032 (IN $ MILLION)

LIST OF FIGURES
FIGURE 1: PORTER’S FIVE FORCES ANALYSIS
FIGURE 2: MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY PROCEDURE, 2023 & 2032 (IN %)
FIGURE 3: MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY LAPAROSCOPY, 2024-2032 (IN $ MILLION)
FIGURE 4: MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY ORTHOPEDIC SURGERY, 2024-2032 (IN $ MILLION)
FIGURE 5: MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY CARDIOVASCULAR, 2024-2032 (IN $ MILLION)
FIGURE 6: MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY OBSTETRICS AND GYNECOLOGY, 2024-2032 (IN $ MILLION)
FIGURE 7: MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY WOUND CLOSURE, 2024-2032 (IN $ MILLION)
FIGURE 8: MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY PLASTIC & RECONSTRUCTIVE SURGERY, 2024-2032 (IN $ MILLION)
FIGURE 9: MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY THORACIC SURGERY, 2024-2032 (IN $ MILLION)
FIGURE 10: MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY MICROVASCULAR, 2024-2032 (IN $ MILLION)
FIGURE 11: MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY UROLOGY, 2024-2032 (IN $ MILLION)
FIGURE 12: MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY NEUROSURGERY, 2024-2032 (IN $ MILLION)
FIGURE 13: MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY OTHER PROCEDURES, 2024-2032 (IN $ MILLION)
FIGURE 14: MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY TYPE OF INFECTION, 2023 & 2032 (IN %)
FIGURE 15: MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY SUPERFICIAL INCISIONAL SSI, 2024-2032 (IN $ MILLION)
FIGURE 16: MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY DEEP INCISIONAL SSI, 2024-2032 (IN $ MILLION)
FIGURE 17: MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY ORGAN OR SPACE SSI, 2024-2032 (IN $ MILLION)
FIGURE 18: MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY INDUSTRY VERTICAL, 2023 & 2032 (IN %)
FIGURE 19: MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY HOSPITALS, 2024-2032 (IN $ MILLION)
FIGURE 20: MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY AMBULATORY SURGICAL CENTERS, 2024-2032 (IN $ MILLION)
FIGURE 21: MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY PRODUCT, 2023 & 2032 (IN %)
FIGURE 22: MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY DISINFECTANTS, 2024-2032 (IN $ MILLION)
FIGURE 23: MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY DISINFECTANTS, 2023 & 2032 (IN %)
FIGURE 24: MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY SKIN DISINFECTANTS, 2024-2032 (IN $ MILLION)
FIGURE 25: MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY HAND DISINFECTANTS, 2024-2032 (IN $ MILLION)
FIGURE 26: MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY MANUAL REPROCESSORS SOLUTIONS, 2024-2032 (IN $ MILLION)
FIGURE 27: MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY SURGICAL DRAPES, 2024-2032 (IN $ MILLION)
FIGURE 28: MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY SURGICAL GLOVES, 2024-2032 (IN $ MILLION)
FIGURE 29: MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY SKIN PREPARATION SOLUTIONS, 2024-2032 (IN $ MILLION)
FIGURE 30: MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY SURGICAL IRRIGATION, 2024-2032 (IN $ MILLION)
FIGURE 31: MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY SURGICAL SCRUBS, 2024-2032 (IN $ MILLION)
FIGURE 32: MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY HAIR CLIPPERS, 2024-2032 (IN $ MILLION)
FIGURE 33: MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY MEDICAL NONWOVENS, 2024-2032 (IN $ MILLION)
FIGURE 34: MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY OTHER PRODUCTS, 2024-2032 (IN $ MILLION)
FIGURE 35: MIDDLE EAST AND AFRICA SURGICAL SITE INFECTION CONTROL MARKET, BY COUNTRY OUTLOOK, 2023 & 2032 (IN %)
FIGURE 36: UNITED ARAB EMIRATES SURGICAL SITE INFECTION CONTROL MARKET 2024-2032 (IN $ MILLION)
FIGURE 37: SAUDI ARABIA SURGICAL SITE INFECTION CONTROL MARKET 2024-2032 (IN $ MILLION)
FIGURE 38: TURKEY SURGICAL SITE INFECTION CONTROL MARKET 2024-2032 (IN $ MILLION)
FIGURE 39: SOUTH AFRICA SURGICAL SITE INFECTION CONTROL MARKET 2024-2032 (IN $ MILLION)
FIGURE 40: ISRAEL SURGICAL SITE INFECTION CONTROL MARKET 2024-2032 (IN $ MILLION)
FIGURE 41: REST OF MIDDLE EAST & AFRICA SURGICAL SITE INFECTION CONTROL MARKET 2024-2032 (IN $ MILLION)